PE20121390A1 - DERIVADOS DE 2-(1H-PIRAZOLO[3,4-d]PIRIMIDIN-1-ILMETIL)QUINAZOLIN-4(3H)-ONA - Google Patents
DERIVADOS DE 2-(1H-PIRAZOLO[3,4-d]PIRIMIDIN-1-ILMETIL)QUINAZOLIN-4(3H)-ONAInfo
- Publication number
- PE20121390A1 PE20121390A1 PE2012000506A PE2012000506A PE20121390A1 PE 20121390 A1 PE20121390 A1 PE 20121390A1 PE 2012000506 A PE2012000506 A PE 2012000506A PE 2012000506 A PE2012000506 A PE 2012000506A PE 20121390 A1 PE20121390 A1 PE 20121390A1
- Authority
- PE
- Peru
- Prior art keywords
- pyrimidin
- alkyl
- pyrazolo
- chlorobenzyl
- hydroxyphenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE 2-(1H-PIRAZOLO[3,4-d]PIRIMIDIN-1-ILMETIL)QUINAZOLIN-4(3H)-ONA DE FORMULA (I) DONDE R1 ES H, ALQUILO(C1-C15) EN DONDE UNO O VARIOS CARBONOS PUEDEN SER REEMPLAZADOS POR UN HETEROATOMO TAL COMO O, N, ENTRE OTROS Y ESTA OPCIONALMENTE SUSTITUIDA CON HALOGENO, ARILO, HETEROARILO, ENTRE OTROS; R3a ES HIDROXILO; R3b ES H, HIDROXILO, HALO, CN, ENTRE OTROS; R4 Y R5 SON CADA UNO H O ALQUILO(C1-C3); X ES ARILO(C6-C10) O HETEROARILO(C5-C9) SUSTITUIDO CON R2a Y R2b, EN DONDE R2a ES H, ALQUILO(C1-C3), HALO, CN, ENTRE OTROS; R2b ES H, ALQUILO(C1-C3), HALO, HALOALQUILO(C1-C3). SON COMPUESTOS PREFERIDOS: 2-((4-AMINO-3-(3-HIDROXIFENIL)-1H-PIRAZOLO[3,4-d]PIRIMIDIN-1-IL)METIL)-3-(2-CLOROBENCIL)-5-ETINILQUINAZOLIN-4(3H)-ONA; 6-(2-((4-AMINO-3-(4-HIDROXIFENIL)-1H-PIRAZOLO[3,4-d]PIRIMIDIN-1-IL)METIL)-3-(2-CLOROBENCIL)-4-OXO-3,4-DIHIDROQUINAZOLIN-5-IL)HEX-5-INOICO; 2-ACETAMIDO-N-(3-(2-((4-AMINO-3-(3-HIDROXIFENIL)-1H-PIRAZOLO[3,4-d]PIRIMIDIN-1-IL)METIL)-3-(2-CLOROBENCIL)-4-OXO-3,4-DIHIDROQUINAZOLIN-5-IL)PROP-2-IN-1-IL)ACETAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE FOSFOINOSITIDA 3-QUINASAS (PI3 QUINASAS) SIENDO UTILES EN EL TRATAMIENTO DE ASMA, FIBROSIS QUISTICA, SINUSITIS, DERMATITIS ALERGICA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0918249.4A GB0918249D0 (en) | 2009-10-19 | 2009-10-19 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20121390A1 true PE20121390A1 (es) | 2012-10-15 |
Family
ID=41462531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012000506A PE20121390A1 (es) | 2009-10-19 | 2010-10-19 | DERIVADOS DE 2-(1H-PIRAZOLO[3,4-d]PIRIMIDIN-1-ILMETIL)QUINAZOLIN-4(3H)-ONA |
Country Status (35)
Country | Link |
---|---|
US (4) | US8741909B2 (es) |
EP (1) | EP2491037B1 (es) |
JP (1) | JP5889792B2 (es) |
KR (1) | KR101770616B1 (es) |
CN (1) | CN102712645B (es) |
AR (1) | AR078674A1 (es) |
AU (1) | AU2010309832B2 (es) |
BR (1) | BR112012009214A2 (es) |
CA (1) | CA2777902C (es) |
CL (1) | CL2012000981A1 (es) |
CR (1) | CR20120264A (es) |
CY (1) | CY1116057T1 (es) |
DK (1) | DK2491037T3 (es) |
EA (1) | EA020330B3 (es) |
EC (1) | ECSP12011805A (es) |
ES (1) | ES2477270T3 (es) |
GB (1) | GB0918249D0 (es) |
HK (1) | HK1173728A1 (es) |
HR (1) | HRP20140599T1 (es) |
IL (1) | IL219248A (es) |
ME (1) | ME02064B (es) |
MX (1) | MX2012004525A (es) |
MY (1) | MY164731A (es) |
NI (2) | NI201200061A (es) |
NZ (2) | NZ599162A (es) |
PE (1) | PE20121390A1 (es) |
PL (1) | PL2491037T3 (es) |
PT (1) | PT2491037E (es) |
RS (1) | RS53385B (es) |
SI (1) | SI2491037T1 (es) |
SM (1) | SMT201400086B (es) |
TW (1) | TWI478923B (es) |
UA (1) | UA108743C2 (es) |
WO (1) | WO2011048111A1 (es) |
ZA (1) | ZA201203662B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0821227A2 (pt) | 2007-12-19 | 2015-06-16 | Cancer Rec Tech Ltd | Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos |
GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
AU2011209586B2 (en) | 2010-02-01 | 2016-01-21 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro- 4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo [4,5-b]pyridin-7-yloxy)-phenyl] -urea and related compounds and their use in therapy |
UY33337A (es) * | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
EA029473B1 (ru) | 2011-12-15 | 2018-03-30 | Новартис Аг | Применение ингибиторов pi3k для лечения острой и церебральной малярии |
TWI586378B (zh) * | 2012-03-13 | 2017-06-11 | 瑞斯比維特有限公司 | 新穎醫藥調配物 |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9737521B2 (en) | 2012-11-08 | 2017-08-22 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor |
TW201522341A (zh) | 2013-03-15 | 2015-06-16 | Respivert Ltd | 化合物 |
AR095353A1 (es) | 2013-03-15 | 2015-10-07 | Respivert Ltd | Compuesto |
EP3007711B1 (en) | 2013-06-14 | 2020-10-21 | Psioxus Therapeutics Limited | A dosing regime and formulations for type b adenoviruses |
EA201690713A1 (ru) | 2013-10-04 | 2016-08-31 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
GB201510197D0 (en) | 2014-06-12 | 2015-07-29 | Psioxus Therapeutics Ltd | Method of treating ovarian cancer |
CU24428B1 (es) | 2014-07-04 | 2019-06-04 | Lupin Ltd | Derivados de quinolizinona como inhibidores de pi3k |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
NZ740616A (en) | 2015-09-14 | 2023-05-26 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
AU2019209960B2 (en) | 2018-01-20 | 2023-11-23 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
CN108516976B (zh) * | 2018-04-27 | 2020-07-03 | 四川大学华西医院 | 一种7-脱氮嘌呤衍生物及其四元环超分子结构 |
US20220041603A1 (en) * | 2018-09-18 | 2022-02-10 | Societe Des Produits Nestle S.A. | Src inhibitor compounds for skeletal muscle modulation, methods and uses thereof |
CN114258393A (zh) * | 2020-07-21 | 2022-03-29 | 中国医药研究开发中心有限公司 | 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1204826B (it) | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche per inalazione |
GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
PT1283036E (pt) | 1998-11-13 | 2008-03-06 | Jagotec Ag | Inalador de pó seco de dose múltipla com um reservatório de pó |
AU779008C (en) | 1999-01-11 | 2005-06-30 | Princeton University | High affinity inhibitors for target validation and uses thereof |
TR200102567T2 (tr) | 1999-03-05 | 2002-01-21 | Chiesi Farmaceutici S.P.A. | İnhalasyon için geliştirilmiş toz halindeki farmasötik bileşimler |
PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
DE60144277D1 (de) | 2000-04-25 | 2011-05-05 | Icos Corp | Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
AU5261001A (en) | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
JP2005509594A (ja) | 2001-07-13 | 2005-04-14 | バーチャル ドラッグ ディヴェロップメント、インコーポレイティッド | Nadシンテターゼ阻害剤およびその使用 |
AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
AU2003301662A1 (en) | 2002-10-21 | 2004-05-13 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
CA2517888C (en) | 2003-03-14 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
JP2007524605A (ja) | 2003-04-03 | 2007-08-30 | ピーディーエル バイオファーマ,インコーポレイティド | インテグリンα5β1のインヒビターおよび組織顆粒化の制御のためのそれらの使用 |
US7429596B2 (en) | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
GB0316341D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Pharmaceutical formulations |
EP1661879A4 (en) | 2003-08-04 | 2006-11-29 | Ono Pharmaceutical Co | A DIPHENYL ETHER COMPOUND, PROCESS FOR THE PRODUCTION AND USE THEREOF |
US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
US20050043239A1 (en) | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
GB0326632D0 (en) | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
CA2552664A1 (en) | 2004-01-08 | 2005-07-28 | Michigan State University | Methods for treating and preventing hypertension and hypertension-related disorders |
CN101031569B (zh) * | 2004-05-13 | 2011-06-22 | 艾科斯有限公司 | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 |
EP1750714A1 (en) | 2004-05-13 | 2007-02-14 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
JP2008500338A (ja) | 2004-05-25 | 2008-01-10 | イコス・コーポレイション | 造血細胞の異常増殖を治療及び/又は予防する方法 |
WO2005120511A1 (en) | 2004-06-04 | 2005-12-22 | Icos Corporation | Methods for treating mast cell disorders |
TWI400232B (zh) | 2004-09-13 | 2013-07-01 | Ono Pharmaceutical Co | 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑 |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
US20080287469A1 (en) | 2005-02-17 | 2008-11-20 | Diacovo Thomas G | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation |
GB0525254D0 (en) | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
SI2004654T1 (sl) * | 2006-04-04 | 2013-11-29 | The Regents Of The University Of California | Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti |
US7585868B2 (en) * | 2006-04-04 | 2009-09-08 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists |
WO2007134876A2 (en) | 2006-05-24 | 2007-11-29 | Bayer Schering Pharma Aktiengesellschaft | HIGH AFFINITY HUMAN AND HUMANIZED ANTI-α5β1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY |
AR061664A1 (es) | 2006-06-29 | 2008-09-10 | Schering Corp | Derivados de himbacina como antagonistas del receptor de trombina biciclicos y triciclicos sustituidos. composiciones farmaceuticas. |
GB0622818D0 (en) | 2006-11-15 | 2006-12-27 | Jagotec Ag | Improvements in or relating to organic compounds |
WO2008058402A1 (en) | 2006-11-17 | 2008-05-22 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
US20090035306A1 (en) | 2006-11-29 | 2009-02-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
EP2137158A4 (en) | 2007-02-28 | 2012-04-18 | Methylgene Inc | LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS) |
PE20090215A1 (es) * | 2007-05-09 | 2009-03-30 | Novartis Ag | Compuestos derivados de imidazopiridazinas como inhibidores de cinasa |
WO2008140750A1 (en) | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
WO2009088990A1 (en) * | 2008-01-04 | 2009-07-16 | Intellikine, Inc. | Certain chemical entities, compositions and methods |
WO2010036380A1 (en) * | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
WO2010059593A1 (en) | 2008-11-18 | 2010-05-27 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
CA2745280A1 (en) | 2008-12-04 | 2010-06-10 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders |
EP2379505A4 (en) | 2008-12-05 | 2012-10-17 | Designmedix Inc | MODIFIED CHLOROQUINE WITH SINGLE RING UNIT OR CONDENSED RING UNIT |
US20110135655A1 (en) * | 2009-01-13 | 2011-06-09 | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication |
BRPI1012333A2 (pt) * | 2009-03-24 | 2016-03-29 | Gilead Calistoga Llc | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso |
MX2012001504A (es) | 2009-08-05 | 2012-06-01 | Versitech Ltd | Compuestos antivirales y metodos para elaborarlos y usarlos. |
GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
CA2813096C (en) | 2010-09-30 | 2019-10-29 | Chiesi Farmaceutici S.P.A. | Use of magnesium stearate in dry powder formulations for inhalation |
UY33337A (es) * | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
TWI586378B (zh) | 2012-03-13 | 2017-06-11 | 瑞斯比維特有限公司 | 新穎醫藥調配物 |
-
2009
- 2009-10-19 GB GBGB0918249.4A patent/GB0918249D0/en not_active Ceased
-
2010
- 2010-10-18 TW TW099135360A patent/TWI478923B/zh not_active IP Right Cessation
- 2010-10-19 DK DK10771416.4T patent/DK2491037T3/da active
- 2010-10-19 AU AU2010309832A patent/AU2010309832B2/en not_active Ceased
- 2010-10-19 AR ARP100103812A patent/AR078674A1/es unknown
- 2010-10-19 RS RS20140344A patent/RS53385B/en unknown
- 2010-10-19 JP JP2012534671A patent/JP5889792B2/ja not_active Expired - Fee Related
- 2010-10-19 BR BR112012009214A patent/BR112012009214A2/pt not_active IP Right Cessation
- 2010-10-19 EP EP10771416.4A patent/EP2491037B1/en active Active
- 2010-10-19 KR KR1020127012826A patent/KR101770616B1/ko active IP Right Grant
- 2010-10-19 WO PCT/EP2010/065746 patent/WO2011048111A1/en active Application Filing
- 2010-10-19 NZ NZ599162A patent/NZ599162A/xx not_active IP Right Cessation
- 2010-10-19 PT PT107714164T patent/PT2491037E/pt unknown
- 2010-10-19 ES ES10771416.4T patent/ES2477270T3/es active Active
- 2010-10-19 US US13/502,465 patent/US8741909B2/en not_active Expired - Fee Related
- 2010-10-19 CN CN201080047955.2A patent/CN102712645B/zh not_active Expired - Fee Related
- 2010-10-19 PE PE2012000506A patent/PE20121390A1/es not_active Application Discontinuation
- 2010-10-19 PL PL10771416T patent/PL2491037T3/pl unknown
- 2010-10-19 CA CA2777902A patent/CA2777902C/en not_active Expired - Fee Related
- 2010-10-19 SI SI201030660T patent/SI2491037T1/sl unknown
- 2010-10-19 EA EA201270575A patent/EA020330B3/ru not_active IP Right Cessation
- 2010-10-19 UA UAA201203872A patent/UA108743C2/ru unknown
- 2010-10-19 MX MX2012004525A patent/MX2012004525A/es active IP Right Grant
-
2011
- 2011-10-18 MY MYPI2013700611A patent/MY164731A/en unknown
- 2011-10-18 NZ NZ609147A patent/NZ609147A/en not_active IP Right Cessation
- 2011-10-18 ME MEP-2015-43A patent/ME02064B/me unknown
-
2012
- 2012-04-17 EC ECSP12011805 patent/ECSP12011805A/es unknown
- 2012-04-18 NI NI201200061A patent/NI201200061A/es unknown
- 2012-04-18 CL CL2012000981A patent/CL2012000981A1/es unknown
- 2012-04-18 IL IL219248A patent/IL219248A/en not_active IP Right Cessation
- 2012-05-18 ZA ZA2012/03662A patent/ZA201203662B/en unknown
- 2012-05-21 CR CR20120264A patent/CR20120264A/es unknown
-
2013
- 2013-01-18 HK HK13100837.2A patent/HK1173728A1/xx not_active IP Right Cessation
- 2013-04-16 NI NI201300035A patent/NI201300035A/es unknown
-
2014
- 2014-03-20 US US14/220,650 patent/US9321773B2/en not_active Expired - Fee Related
- 2014-06-26 HR HRP20140599AT patent/HRP20140599T1/hr unknown
- 2014-06-30 SM SM201400086T patent/SMT201400086B/xx unknown
- 2014-07-29 CY CY20141100570T patent/CY1116057T1/el unknown
-
2016
- 2016-03-31 US US15/086,120 patent/US9834560B2/en not_active Expired - Fee Related
-
2017
- 2017-11-08 US US15/806,742 patent/US20180118754A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20121390A1 (es) | DERIVADOS DE 2-(1H-PIRAZOLO[3,4-d]PIRIMIDIN-1-ILMETIL)QUINAZOLIN-4(3H)-ONA | |
PE20141588A1 (es) | Nuevos derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas del receptor de canabinoides 2 | |
PE20081612A1 (es) | Analogos de las pterinas | |
PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
PE20091561A1 (es) | Compuestos inhibidores de raf y metodos para su uso | |
PE20120493A1 (es) | Pirimidinonas como inhibidores de pi3k | |
PE20141578A1 (es) | Derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas del receptor de canabinoides 2 | |
PE20141973A1 (es) | Compuestos de heterociclilo como inhibidores de mek | |
HK1214591A1 (zh) | -氨基- -氟- -羥基苯基 -吡唑並 嘧啶- -基 甲基 三氟甲基 苄基 喹唑啉- -酮衍生物和其作爲磷酸肌醇 -激酶抑制劑的用途 | |
PE20110545A1 (es) | Compuestos de triazolopiridina como inhibidores de jak | |
PE20120534A1 (es) | PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt | |
PE20060833A1 (es) | Derivados de purina como agonistas del receptor a2a de adenosina | |
PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
PE20110575A1 (es) | INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT | |
PE20110922A1 (es) | DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1) | |
CL2008001345A1 (es) | Compuestos derivados de imidazo[1,2-b]piridazinas, inhibidores de cinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su proceso de preparacion; y su uso en enfermedades hiperproliferativas, inflamatorias, alergicas y obstructivas de las vias respiratorias, entre otras. | |
MY152386A (en) | Substituted 6a,7,8,9-tetrahydropyrido[3,2-e] pyrrolo[1,2-a]pyrazin-6(5h)-ones | |
PE20170333A1 (es) | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados | |
PE20141540A1 (es) | Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 | |
PE20140245A1 (es) | Compuesto de furo[3,2-d]pirimidina | |
HRP20191180T1 (hr) | Imidazopirazinoni kao inhibitori pde1 | |
PE20160648A1 (es) | Compuestos espirociclicos como inhibidores de triptofano hidroxilasa | |
BRPI0810411A2 (pt) | Derivados de sulfonil amida para o tratamento de crescimento celular anormal | |
PE20100138A1 (es) | Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k | |
PA8783501A1 (es) | Derivados de quinaxolina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |